<DOC>
	<DOCNO>NCT02478502</DOCNO>
	<brief_summary>Germ cell tumor belong chemosensitive malignancy . Paclitaxel combination ifosfamide cisplatin ( TIP ) become common regimen salvage treatment germ cell cancer . Cabazitaxel may overcome resistance docetaxel paclitaxel might clinical activity patient metastatic progressive germ cell tumor .</brief_summary>
	<brief_title>Testis CAB : Cabazitaxel Salvage Treatment Cisplatin-resistant Germ Cell Cancer</brief_title>
	<detailed_description>Patients metastatic germ cell cancer relapse two course cisplatin-based chemotherapy high-dose chemotherapy poor prognosis curative option . Taxanes various combination unfold cytotoxic effect germ cell tumor resistant conventional dos cisplatin . Paclitaxel combination ifosfamide cisplatin ( TIP ) become common regimen salvage treatment germ cell cancer . In patient , however , resistance paclitaxel , evidence progression occurs.Cabazitaxel develop overcome resistance docetaxel paclitaxel . It show efficacy patient progress docetaxel therapy large phase III trial ( TROPIC ) patient castration-resistant prostate cancer . Furthermore , chemotherapy resistance might less likely develop patient receive cabazitaxel compare taxanes .</detailed_description>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Male patient ≥ 18 year old Histologically verify metastatic germ cell cancer ( GCC ) testicle extragonadal GCC originate retroperitoneum mediastinum Disease progression cisplatinbased chemotherapy Disease progression relapse highdose chemotherapy Disease progression relapse least 2 different cisplatinbased regimen Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) : 02 Life expectancy ≥ 3 month At baseline adequate function liver , kidneys bone marrow : ·Neutrophils ≥ 1.5 x 109/L· Hemoglobin ≥ 9.0 g/dL Platelets ≥ 100 x 109/L Creatinine ≤ 1.5 x upper limit normal ( ULN ) Total Bilirubin ≤ 1.0 x ULN Serum glutamate oxaloacetate transaminase ( SGOT/AST ) ≤ 1.5 x ULN Serum glutamate pyruvate transaminase ( SGPT/ALT ) &lt; 1.5 x ULN Systemic antitumor treatment within 21 day study entry Simultaneous radiotherapy target lesion Patients unwilling unable comply protocol Patients unstable angina pectoris , myocardial infarction ≤ 6 month prior first study treatment , congestive heart failure New York Heart Association ( NYHA ) IIIIV serious uncontrolled cardiac arrhythmia Patients active uncontrolled infection Patients history another primary malignancy treatment ≤ 3 year , exception nonmelanoma skin cancer Patients undergone major surgery within 4 week prior start study drug ( e.g . intrathoracic , intraabdominal , intrapelvic ) significant traumatic injury , recover side effect within 6 week Patients participate another interventional clinical trial within 30 day study entry Other serious medical condition could impair ability patient participate study Active infection require systemic antibiotic , antiviral , antifungal medication Neuropathy ≥Grade 2 Common Terminology Criteria Adverse Events ( CTCAE ) Patient reproductive potential implementing accept effective method contraception whole study period 6 month last dose cabazitaxel One follow cabazitaxelspecific requirement : History severe hypersensitivity reaction ( ≥ Grade 3 ) docetaxel History severe hypersensitivity reaction ( ≥ Grade 3 ) polysorbate 80 contain drug Concurrent plan treatment strong inhibitor strong inducer cytochrome P450 3A4 ( CYP3A4 ) ( one week washout period necessary patient already treatment ) ( see Appendix A B ) Concurrent plan treatment Organic anion transport polypeptide1B1 ( OATP1B1 ) substrates e.g . statin , valsartan , repaglinide take within 12 hour cabazitaxel application 3 hour end infusion , refer table 9</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>testicular cancer</keyword>
	<keyword>cisplatin resistancy</keyword>
</DOC>